The Latest Cardiac and Vascular News
SOUTHLAKE, Texas, July 18, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced raising $47 million from the initial closings of a Series B financing. Proceeds from the financing will be used to […]
SOUTHLAKE, Texas, July 11, 2023 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the […]
-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery- –RBT-1 treatment demonstrated a statistically significant reduction in ICU days and 30-day cardiopulmonary […]
-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery- –RBT-1 treatment demonstrated a reduction in time on ventilator, ICU days, length of […]
-Ms. Ramdas has more than 25 years of healthcare experience, including at Amgen and Johnson & Johnson- SOUTHLAKE, Texas, Dec. 13, 2022 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced the appointment […]
-RBT-1 interim results from a randomized double-blind placebo-controlled study showed statistically significant reductions in days on ventilator and days in ICU. 30-day hospital readmission was reduced by greater than 90% -(<0.0027)- -RBT-1 was recently granted Fast Track Designation from U.S. […]
